Hope S Rugo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/818381/publications.pdf

Version: 2024-02-01

382	48,988	2538	1895
papers	citations	96 h-index	208 g-index

391	391	391	42869
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018, 379, 2108-2121.	13.9	3,097
2	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	13.9	2,474
3	Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1925-1936.	13.9	1,943
4	Alpelisib for PIK3CA-Mutated, Hormone Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940.	13.9	1,582
5	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	7.7	1,486
6	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine, 2018, 379, 753-763.	13.9	1,472
7	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, The, 2020, 396, 1817-1828.	6.3	992
8	Effect of interleukin-1Î² inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	6.3	948
9	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	13.9	854
10	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848
11	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 44-59.	5.1	826
12	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell, 2014, 26, 623-637.	7.7	751
13	T-Cellâ€“Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 2019, 37, 318-327.	0.8	656
14	Breast Cancerâ€”Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 290-303.	157.7	649
15	Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) â€“Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology, 2011, 29, 398-405.	0.8	647
16	The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature, 2014, 511, 319-325.	13.7	610
17	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
18	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	13.9	598

#	Article	IF	Citations
19	Phase II Trial of Bicalutamide in Patients with Androgen Receptorâ€“Positive, Estrogen Receptorâ€“Negative Metastatic Breast Cancer. Clinical Cancer Research, 2013, 19, 5505-5512.	3.2	592
20	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	0.8	582
21	Cancer-Related Fatigue, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1012-1039.	2.3	581
22	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	13.9	542
23	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 497-509.	5.1	530
24	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	3.2	492
25	Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2008, 26, 1810-1816.	0.8	475
26	Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology, 2005, 23, 5474-5483.	0.8	470
27	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	13.9	467
28	Endocrine Therapy for Hormone Receptorâ€“Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, 2016, 34, 3069-3103.	0.8	456
29	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 2013, 30, 870-884.	1.3	430
30	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	3.4	419
31	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2615-2623.	0.8	413
32	Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2796-2801.	3.3	393
33	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€“Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology, 2017, 35, 2535-2541.	0.8	383
34	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4286-4293.	0.8	379
35	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIALâ€”CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology, 2012, 30, 3242-3249.	0.8	379
36	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1â€“Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology, 2017, 35, 4035-4041.	0.8	375

#	Article	IF	Citations
37	Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. International Immunology, 1990, 2, 821-832.	1.8	357
38	Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 691-722.	2.3	357
39	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
40	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1902-1909.	0.8	351
41	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2012, 30, 3234-3241.	0.8	319
42	Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research, 2011, 17, 4834-4843.	3.2	318
43	Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299.	0.8	298
44	Management of Cancer Cachexia: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 2438-2453.	0.8	292
45	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>â€158 and <scp>KEYNOTE</scp>â€028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	2.3	288
46	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 2012, 132, 1049-1062.	1.1	286
47	Immune microenvironments in solid tumors: new targets for therapy. Genes and Development, 2011, 25, 2559-2572.	2.7	277
48	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study. Journal of Clinical Oncology, 2005, 23, 5464-5473.	0.8	271
49	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research, 2013, 19, 3693-3702.	3.2	270
50	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6.	7.7	270
51	Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment, 2019, 174, 719-729.	1.1	265
52	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3840-3847.	0.8	253
53	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 2804-2811.	3.2	249
54	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1868-1875.	0.8	229

#	Article	IF	Citations
55	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. JAMA Oncology, 2021, 7, 573.	3.4	217
56	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal of Clinical Oncology, 2014, 32, 2142-2150.	0.8	207
57	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	0.8	203
58	Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 904-931.	2.3	201
59	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	0.8	197
60	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptorâ€“Positive Advanced Breast Cancer. JAMA Oncology, 2019, 5, e184475.	3.4	187
61	NCCN GuidelinesÂ® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 484-493.	2.3	186
62	Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial. Journal of Clinical Oncology, 2001, 19, 3771-3779.	0.8	185
63	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. Annals of Surgical Oncology, 2001, 8, 549-559.	0.7	185
64	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist, 2016, 21, 1165-1175.	1.9	183
65	An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Targeted Oncology, 2021, 16, 255-282.	1.7	182
66	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal of the National Cancer Institute, 2021, 113, 1005-1016.	3.0	171
67	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	5.1	169
68	Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 118-126.	2.3	158
69	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncology, The, 2021, 22, 489-498.	5.1	157
70	Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 654-662.	5.1	154
71	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	0.8	153
72	Image-Detected Breast Cancer: State-of-the-Art Diagnosis and Treatment. Journal of the American College of Surgeons, 2009, 209, 504-520.	0.2	147

#	Article	IF	Citations
73	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	1.1	140
74	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine, 2016, 22, 1321-1329.	15.2	138
75	NCCN Guidelines Insights: Antiemesis, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 883-893.	2.3	137
76	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2020, 38, 1000-1000.	0.8	135
77	Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. Journal of Clinical Oncology, 2010, 28, 77-82.	0.8	131
78	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)â€“Positive Metastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 37.	3.8	129
79	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128
80	Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 606.	3.8	127
81	Quantitative and Clinical Description of Postural Instability in Women With Breast Cancer Treated With Taxane Chemotherapy. Archives of Physical Medicine and Rehabilitation, 2007, 88, 1002-1008.	0.5	123
82	Endocrine Treatment and Targeted Therapy for Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3959-3977.	0.8	121
83	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-NaÃ¯ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	3.2	120
84	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	3.4	119
85	Senior Adult Oncology, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 82-126.	2.3	116
86	Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer. JAMA Oncology, 2017, 3, 313.	3.4	115
87	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature Communications, 2020, 11, 3584.	5.8	115
88	A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 7878-7883.	3.2	109
89	Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Research and Treatment, 2012, 132, 1107-1118.	1.1	109
90	Senior Adult Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 162-209.	2.3	105

#	Article	IF	Citations
91	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptorâ€“Positive Breast Cancer in BOLERO-2. Clinical Breast Cancer, 2013, 13, 421-432.e8.	1.1	104
92	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1520-1541.	2.3	104
93	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Annals of Oncology, 2018, 29, 888-894.	0.6	104
94	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Research and Treatment, 2012, 133, 1067-1075.	1.1	103
95	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research, 2019, 25, 2717-2724.	3.2	102
96	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	0.8	101
97	Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. Journal of the National Cancer Institute, 2013, 105, 104-112.	3.0	100
98	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of Oncology, 2020, 31, 1001-1010.	0.6	99
99	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	0.8	99
100	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 2017, 3, 1043.	3.4	98
101	Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2459-2465.	0.8	95
102	Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. Journal of Cancer Survivorship, 2012, 6, 324-332.	1.5	95
103	Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer (ER+/HER2â^' ABC): Analyses from PALOMA-2.. Journal of Clinical Oncology, 2022, 40, LBA1003-LBA1003.	0.8	95
104	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. Journal of Clinical Oncology, 2015, 33, 340-348.	0.8	94
105	Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. International Journal of Hyperthermia, 2014, 30, 285-294.	1.1	93
106	Genomic Profiling of Isolated Circulating Tumor Cells from Metastatic Breast Cancer Patients. Cancer Research, 2013, 73, 30-40.	0.4	92
107	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell, 2022, 40, 609-623.e6.	7.7	92
108	A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 6897-6904.	3.2	90

#	Article	IF	Citations
109	Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment, 2007, 105, 17-28.	1.1	89
110	Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381.	3.2	89
111	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. Journal of the National Cancer Institute, 2013, 105, 654-663.	3.0	88
112	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	0.8	88
113	Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985423.	1.4	87
114	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxelâ€“Treated Advanced Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1733-1743.	3.0	83
115	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1357-1370.	2.3	82
116	Healthâ€related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLEROâ€2 trial. Cancer, 2013, 119, 1908-1915.	2.0	81
117	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Surgery, 2020, 155, e195410.	2.2	81
118	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1556-1568.	5.1	79
119	Associations Between Pro- and Anti-Inflammatory Cytokine Genes and Breast Pain in Women Prior to Breast Cancer Surgery. Journal of Pain, 2012, 13, 425-437.	0.7	78
120	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research, 2015, 21, 2911-2915.	3.2	77
121	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
122	Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clinical Breast Cancer, 2016, 16, 8-17.	1.1	75
123	Everolimus plus exemestane as first-line therapy in HR+, HER2â^' advanced breast cancer in BOLERO-2. Breast Cancer Research and Treatment, 2014, 143, 459-467.	1.1	74
124	A clinicianâ€™s guide to biosimilars in oncology. Cancer Treatment Reviews, 2016, 46, 73-79.	3.4	74
125	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 591-601.	1.1	72
126	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 12-22.	2.3	70

#	Article	IF	Citations
127	Management of breast cancer diagnosed during pregnancy. Current Treatment Options in Oncology, 2003, 4, 165-173.	1.3	69
128	The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Seminars in Oncology, 2003, 30, 749-762.	0.8	69
129	Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of Oncology, 2016, 27, 519-525.	0.6	68
130	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	3.4	68
131	Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (Pts) with hormone receptorâ€“positive/HER2-negative (HR+/HER2-) advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, LBA1001-LBA1001.	0.8	68
132	Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. Journal of Neuro-Oncology, 2008, 88, 359-365.	1.4	67
133	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 145, 725-734.	1.1	67
134	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Npj Breast Cancer, 2022, 8, 23.	2.3	67
135	Chemotherapy-related amenorrhea after adjuvant paclitaxelâ€“trastuzumab (APT trial). Breast Cancer Research and Treatment, 2015, 151, 589-596.	1.1	65
136	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2017, 3, 31.	2.3	64
137	Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist, 2021, 26, e53-e65.	1.9	64
138	First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. Oncologist, 2013, 18, 501-510.	1.9	63
139	Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2â€“Negative Advanced Breast Cancer That Progressed during or after Bevacizumab. Clinical Cancer Research, 2013, 19, 2745-2754.	3.2	62
140	Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Medicine, 2016, 5, 1897-1907.	1.3	62
141	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clinical Cancer Research, 2019, 25, 2433-2441.	3.2	62
142	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncology, 2020, 16, 705-715.	1.1	62
143	The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression. Cancer Discovery, 2012, 2, 638-651.	7.7	61
144	Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Research and Treatment, 2017, 163, 199-205.	1.1	61

#	Article	IF	Citations
145	Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist, 2020, 25, e439-e450.	1.9	61
146	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. Advances in Therapy, 2020, 37, 3059-3082.	1.3	61
147	Palbociclib plus endocrine therapy in older women with HR+/HER2â€“ advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer, 2018, 101, 123-133.	1.3	59
148	Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1331-1339.	2.3	58
149	The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opinion on Drug Safety, 2010, 9, 335-346.	1.0	58
150	Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Research and Treatment, 2015, 154, 339-349.	1.1	57
151	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 2722-2729.	3.2	57
152	Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Breast Cancer, 2018, 18, 19-28.	1.1	57
153	Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Research, 2015, 17, 73.	2.2	55
154	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	3.0	55
155	Patient and Physician Attitudes Toward Breast Cancer Clinical Trials: Developing Interventions Based on Understanding Barriers. Clinical Breast Cancer, 2005, 6, 45-54.	1.1	54
156	Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 33-38.	1.0	54
157	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1266-1290.	2.3	53
158	Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biology of Blood and Marrow Transplantation, 2000, 6, 50-57.	2.0	52
159	Implementing decision and communication aids to facilitate patient-centered care in breast cancer: A case study. Patient Education and Counseling, 2009, 77, 360-368.	1.0	52
160	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1139-1148.	1.1	52
161	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. Journal of Clinical Oncology, 2020, 38, 1006-1006.	0.8	52
162	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Research and Treatment, 2012, 135, 875-883.	1.1	51

#	Article	IF	Citations
163	Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: Effect of clinical node status at presentation. Journal of the American College of Surgeons, 2004, 199, 856-862.	0.2	50
164	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment, 2015, 149, 439-448.	1.1	50
165	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2â^' Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	1.9	49
166	Correlation of molecular alterations with efficacy of everolimus in hormone receptorâ€"positive, HER2-negative advanced breast cancer: Results from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, LBA509-LBA509.	0.8	49
167	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 134, 13-20.	1.1	48
168	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment, 2019, 175, 5-15.	1.1	48
169	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2â€negative breast cancer. Cancer, 2014, 120, 2657-2664.	2.0	47
170	Fertility preservation with ovarian stimulation and time to treatment in women with stage IIâ€"III breast cancer receiving neoadjuvant therapy. Breast Cancer Research and Treatment, 2017, 165, 151-159.	1.1	47
171	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2â^' Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research, 2021, 27, 4177-4185.	3.2	47
172	Role of FcÎ³ receptors in HER2-targeted breast cancer therapy. , 2022, 10, e003171.		47
173	SIS.NET: A randomized controlled trial evaluating a webâ€based system for symptom management after treatment of breast cancer. Cancer, 2015, 121, 893-899.	2.0	46
174	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
175	Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. American Journal of Medicine, 1989, 87, 605-613.	0.6	44
176	Antiemesis. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 456-485.	2.3	44
177	Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Research, 2017, 77, 4530-4541.	0.4	44
178	MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Reports, 2020, 30, 3368-3382.e7.	2.9	44
179	Antiemesis. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 572-595.	2.3	43
180	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	3.4	42

#	Article	IF	Citations
181	Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clinical Cancer Research, 2018, 24, 1486-1499.	3.2	41
182	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 2017, 165, 329-341.	1.1	40
183	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist, 2020, 25, e214-e222.	1.9	39
184	New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature Clinical Practice Oncology, 2009, 6, 25-33.	4.3	38
185	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 141, 461-470.	1.1	38
186	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. Journal of Clinical Oncology, 2018, 36, 1059-1059.	0.8	38
187	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 2017, 25, 1127-1135.	1.0	37
188	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 2021, 7, 603.	3.4	37
189	The role of targeted therapy and biomarkers in breast cancer treatment. Clinical and Experimental Metastasis, 2012, 29, 807-819.	1.7	36
190	Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Therapeutic Advances in Medical Oncology, 2015, 7, 321-339.	1.4	36
191	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications, 2021, 12, 6428.	5.8	36
192	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research, 2015, 21, 1098-1105.	3.2	35
193	An openâ€label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. Cancer, 2012, 118, 4098-4104.	2.0	33
194	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 2018, 29, 271-280.	0.7	33
195	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â€‰Years of Follow-Up. Oncologist, 2021, 26, e749-e755.	1.9	33
196	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment, 2018, 170, 547-557.	1.1	32
197	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
198	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1472-1479.	0.8	31

#	Article	IF	Citations
199	Amelioration of sexual adverse effects in the early breast cancer patient. Journal of Cancer Survivorship, 2010, 4, 247-255.	1.5	30
200	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment, 2019, 176, 303-310.	1.1	30
201	The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations. Current Treatment Options in Oncology, 2007, 8, 47-60.	1.3	29
202	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e40-e54.	1.8	29
203	Oncological care organisation during COVID-19 outbreak. ESMO Open, 2020, 5, e000853.	2.0	29
204	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	3.2	28
205	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist, 2021, 26, 827-834.	1.9	28
206	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Research and Treatment, 2016, 155, 521-530.	1.1	27
207	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. Journal of Clinical Oncology, 2009, 27, 6117-6123.	0.8	26
208	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	1.1	26
209	Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer and Metastasis Reviews, 2006, 25, 279-292.	2.7	25
210	Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 137, 1-12.	1.1	25
211	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Research and Treatment, 2017, 165, 601-609.	1.1	25
212	Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer, 2018, 18, 489-497.	1.1	25
213	Genomewide Metaâ€Analysis Validates a Role for S1PR1 in Microtubule Targeting Agentâ€Induced Sensory Peripheral Neuropathy. Clinical Pharmacology and Therapeutics, 2020, 108, 625-634.	2.3	25
214	Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2^{â^’}advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Current Medical Research and Opinion, 2013, 29, 1463-1473.	0.9	24
215	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	2.2	24
216	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physicianâ€™s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	1.4	24

#	Article	IF	Citations
217	A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 139, 411-419.	1.1	23
218	Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. Npj Breast Cancer, 2018, 4, 31.	2.3	23
219	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer From SOLAR-1. Journal of Clinical Oncology, 2021, 39, 2005-2015.	0.8	23
220	NCCN GuidelinesÂ® Insights: Hematopoietic Growth Factors, Version 1.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 436-442.	2.3	23
221	Bevacizumab for Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 303-319.	0.9	22
222	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2016, 16, 18-22.	1.1	22
223	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	3.0	22
224	A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS ONE, 2015, 10, e0141166.	1.1	22
225	Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. Clinical Advances in Hematology and Oncology, 2014, 12, 3-21; quiz 22.	0.3	22
226	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. Clinical Cancer Research, 2013, 19, 2817-2823.	3.2	21
227	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer, 2020, 20, e173-e180.	1.1	21
228	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment, 2020, 184, 23-35.	1.1	21
229	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Research, 2021, 23, 87.	2.2	21
230	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature Communications, 2022, 13, .	5.8	21
231	Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 312-4.	3.8	20
232	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research and Treatment, 2016, 155, 569-578.	1.1	20
233	Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment, 2018, 167, 117-122.	1.1	20
234	Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. Clinical Breast Cancer, 2010, 10, 288-293.	1.1	19

#	Article	IF	Citations
235	The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Research and Treatment, 2012, 134, 1327-1335.	1.1	19
236	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 150, 605-611.	1.1	19
237	A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. Npj Breast Cancer, 2019, 5, 17.	2.3	19
238	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	3.2	19
239	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology, 2020, 38, 1070-1080.	0.8	19
240	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110.	1.1	19
241	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	0.8	18
242	Change in Topoisomerase 1â€“Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 2018, 24, 3348-3357.	3.2	18
243	Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Research and Treatment, 2019, 177, 401-408.	1.1	18
244	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+â€‰and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Research and Treatment, 2021, 187, 155-165.	1.1	18
245	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research, 2020, 80, CT011-CT011.	0.4	18
246	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 370-382.	0.7	18
247	Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Research and Treatment, 2015, 153, 173-181.	1.1	17
248	Demystifying biosimilars: development, regulation and clinical use. Future Oncology, 2019, 15, 777-790.	1.1	17
249	Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2â€“, PIK3CA-Mutated Breast Cancer. Oncologist, 2021, 26, e1133-e1142.	1.9	17
250	A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Research and Treatment, 2014, 148, 99-106.	1.1	16
251	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 535-544.	1.1	16
252	ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 2019, 15, 2211-2225.	1.1	16

#	Article	IF	Citations
253	Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Cancer Research, 2021, 81, GS3-01-GS3-01.	0.4	16
254	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist, 2021, 26, e1339-e1346.	1.9	16
255	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e40-e54.	1.8	16
256	Practice Patterns in the Delivery of Radiation Therapy After Mastectomy Among the University of California Athena Breast Health Network. Clinical Breast Cancer, 2015, 15, 43-47.	1.1	15
257	Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012;) Tj ETQq1 1 0.784314 rgBT /Over	0.7	15
258	Stomatitis associated with mammalian target of rapamycin inhibition. Journal of the American Dental Association, 2018, 149, 291-298.	0.7	15
259	Achieving Improved Survival Outcomes in Advanced Breast Cancer. New England Journal of Medicine, 2019, 381, 371-372.	13.9	15
260	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 2020, 20, e251-e260.	1.1	15
261	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.. Journal of Clinical Oncology, 2019, 37, 1040-1040.	0.8	15
262	Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210869.	1.4	15
263	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	1.1	15
264	Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable. Clinical Breast Cancer, 2008, 8, 33-37.	1.1	14
265	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 315-326.	0.7	14
266	Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clinical Cancer Research, 2018, 24, 4734-4744.	3.2	14
267	Fixed combination of oral NEPA (netupitantâ€palonosetron) for the prevention of acute and delayed chemotherapyâ€induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, doubleâ€blind phase III studies. Cancer Medicine, 2019, 8, 2064-2073.	1.3	14
268	Clinical Significance of Circulating Tumor Cells in Hormone Receptorâ€“positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clinical Cancer Research, 2020, 26, 4911-4920.	3.2	14
269	Bone Marrow Transplantation Retinopathy in the Absence of Radiation Therapy. American Journal of Ophthalmology, 1996, 122, 268-270.	1.7	13
270	Cytoreduction of Lymphoid Malignancies and Mobilization of Blood Hematopoietic Progenitor Cells with High Doses of Cyclophosphamide and Etoposide Plus Filgrastim. Biology of Blood and Marrow Transplantation, 2006, 12, 316-324.	2.0	13

#	Article	IF	Citations
271	Hormone Therapy in Premenopausal Women with Early-Stage Breast Cancer. New England Journal of Medicine, 2014, 371, 175-176.	13.9	13
272	Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clinical Therapeutics, 2015, 37, 134-144.	1.1	13
273	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer, 2020, 20, 183-193.	1.1	13
274	Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncology, 2012, 8, 1383-1396.	1.1	12
275	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	1.1	12
276	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	0.8	12
277	A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast, 2022, 61, 156-167.	0.9	12
278	A Pharmacogenetic Prediction Model of Progressionâ€Free Survival in Breast Cancer using Genomeâ€Wide Genotyping Data from CALGB 40502 (Alliance). Clinical Pharmacology and Therapeutics, 2019, 105, 738-745.	2.3	11
279	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 4883-4897.	3.2	11
280	The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Management and Research, 2015, 7, 175.	0.9	10
281	Planning for postâ€pandemic cancer care delivery: Recovery or opportunity for redesign?. Ca-A Cancer Journal for Clinicians, 2021, 71, 34-46.	157.7	10
282	Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. Journal of Comparative Effectiveness Research, 2021, 10, 457-467.	0.6	10
283	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. Npj Breast Cancer, 2021, 7, 113.	2.3	10
284	Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 345-348.	1.4	10
285	Strategies for the Prevention of Treatment-Related Bone Loss in Women Receiving Adjuvant Hormonal Therapy. Clinical Breast Cancer, 2007, 7, S21-S28.	1.1	9
286	Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncology, The, 2008, 9, 602-603.	5.1	9
287	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 336-342.	0.5	9
288	The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. Future Oncology, 2018, 14, 2461-2469.	1.1	9

#	Article	IF	Citations
289	Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncology, The, 2021, 22, 27-28.	5.1	9
290	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers, 2021, 13, 2262.	1.7	9
291	A plain language summary of the ASCENTÂstudy: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncology, 2021, 17, 3911-3924.	1.1	9
292	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiâ€institutional study. Cancer, 2015, 121, 1937-1948.	2.0	8
293	Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast, 2017, 33, 76-82.	0.9	8
294	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative metastatic breast cancer. Breast Journal, 2020, 26, 368-375.	0.4	8
295	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Research and Treatment, 2021, 187, 387-395.	1.1	8
296	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	1.4	8
297	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British Journal of Cancer, 2022, 126, 265-274.	2.9	8
298	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
299	Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.. Journal of Clinical Oncology, 2022, 40, 504-504.	0.8	8
300	Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy and Pharmacology, 2004, 53, 468-474.	1.1	7
301	High-Dose Etoposide, Thiotepa, and Dose-Adjusted Carboplatin (TVCa) With Autologous Hematopoietic Stem Cell Rescue as Treatment of Relapsed or Refractory Germ Cell Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 130-137.	0.6	7
302	Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS Journal, 2017, 19, 1411-1423.	2.2	7
303	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€“Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical and Gynecological Survey, 2018, 73, 26-27.	0.2	7
304	Personalized Management of Chemotherapyâ€induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of Clinical Pharmacology, 2020, 60, 444-452.	1.0	7
305	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer, 2021, 21, e575-e583.	1.1	7
306	A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. Clinical Cancer Research, 2021, 27, 4486-4490.	3.2	7

#	Article	IF	Citations
307	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. Cancer Research, 2015, 75, PD5-1-PD5-1.	0.4	7
308	The association of early toxicity and outcomes for patients treated with abemaciclib.. Journal of Clinical Oncology, 2018, 36, 1053-1053.	0.8	7
309	Sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	0.8	7
310	Cost Comparison of Capecitabine in Patients With Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 550-556.	0.6	6
311	Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy. Clinical Cancer Research, 2015, 21, 1511-1513.	3.2	6
312	Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 829-837.	2.3	6
313	Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. American Journal of Hospice and Palliative Medicine, 2019, 36, 143-146.	0.8	6
314	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Research and Treatment, 2020, 181, 623-633.	1.1	6
315	Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab . OncoTargets and Therapy, 2020, Volume 13, 4385-4395.	1.0	6
316	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 188, 369-377.	1.1	6
317	Risk-Based Screening for Cancer in Patients With Dermatomyositis. JAMA Dermatology, 2022, 158, 244.	2.0	6
318	Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. European Journal of Surgical Oncology, 2020, 46, 223-228.	0.5	5
319	A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial. Global Advances in Health and Medicine, 2020, 9, 216495612096471.	0.7	5
320	Methylome Variation Predicts Exemestane Resistance in Advanced ER⁺ Breast Cancer. Technology in Cancer Research and Treatment, 2020, 19, 153303381989633.	0.8	5
321	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Research and Treatment, 2021, 188, 179-190.	1.1	5
322	Temporary amenorrhea predicts future infertility in young women treated with chemotherapy. Journal of Cancer Therapeutics & Research, 2013, 2, 16.	1.2	5
323	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
324	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Frontiers in Oncology, 2022, 12, 802579.	1.3	5

#	Article	IF	Citations
325	The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. , 2022, 10, e004312.		5
326	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 403-418.	0.8	4
327	Circulating Tumors Cells as a Biomarker of Radiation Benefit. JAMA Oncology, 2018, 4, e180194.	3.4	4
328	Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz058.	1.4	4
329	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.. Journal of Clinical Oncology, 2018, 36, 110-110.	0.8	4
330	Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget, 2016, 7, 38359-38366.	0.8	4
331	OUP accepted manuscript. Oncologist, 2022, , .	1.9	4
332	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptorâ€“positive (HR+), human epidermal growth factor receptor 2â€“negative (HER2â^') advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. Journal of Clinical Oncology, 2022, 40, 1006-1006.	0.8	4
333	Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precision Oncology, 2022, , .	1.5	4
334	Hormonal Therapy for Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 273-291.	0.9	3
335	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2â^'metastatic breast cancer receiving single-agent chemotherapyâ€"a comparison with MONARCH 1. Breast Cancer Research and Treatment, 2020, 184, 161-172.	1.1	3
336	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	1.8	3
337	Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Research and Treatment, 2020, 181, 23-29.	1.1	3
338	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast, 2021, 58, 18-26.	0.9	3
339	Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?. Npj Breast Cancer, 2021, 7, 139.	2.3	3
340	Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs: the Investigational Drugs Journal, 2005, 8, 739-54.	0.7	3
341	HER2-positive breast cancer: is more treatment better?. Lancet Oncology, The, 2016, 17, 268-270.	5.1	2
342	The new world of biosimilars in oncology: Translation ofÂdataÂto the clinic. European Journal of Cancer, 2018, 96, 125-127.	1.3	2

#	Article	IF	Citations
343	Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Review of Anticancer Therapy, 2018, 18, 3-18.	1.1	2
344	Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1037-1042.	0.6	2
345	Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data. , 2021, , .		2
346	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. , 2001, 8, 549.		2
347	The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases. Breast, 2022, 63, 149-156.	0.9	2
348	Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.. Journal of Clinical Oncology, 2022, 40, TPS1121-TPS1121.	0.8	2
349	Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptorâ€“negative (HR+/HER2â^') advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology, 2022, 40, 1015-1015.	0.8	2
350	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1118-TPS1118.	0.8	2
351	Use of Neoadjuvant Platinumâ€"The Ongoing Conundrum. JAMA Oncology, 2017, 3, 1312.	3.4	1
352	Dual HER2 Blockade. Breast Care, 2017, 12, 345-349.	0.8	1
353	Trials of Immunotherapy in Triple Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 171-185.	0.5	1
354	Pembrolizumab plus chemotherapy in triple-negative breast cancer â€“ Authors' reply. Lancet, The, 2021, 398, 24-25.	6.3	1
355	Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. Journal of Clinical Oncology, 2014, 32, 151-151.	0.8	1
356	Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. Clinical Advances in Hematology and Oncology, 2017, 15, 607-614.	0.3	1
357	Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. Clinical Advances in Hematology and Oncology, 2019, 17, 555-558.	0.3	1
358	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS611-TPS611.	0.8	1
359	PO139 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B (RANK) EXPRESSION IN PRIMARY BREAST CANCER CORRELATES WITH RECURRENCE FREE SURVIVAL AND DEVELOPMENT OF BONE METASTASES IN THE I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast, 2015, 24, S69-S70.	0.9	0
360	When to Treat, With What, and for How Long: That Is the Question!. Journal of Oncology Practice, 2016, 12, 1160-1162.	2.5	0

#	Article	IF	Citations
361	Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancerâ€"Reply. JAMA Oncology, 2017, 3, 1142.	3.4	0
362	Efficacy + safety of palbociclib (P) in patients (pts) â‰¥50 y with hormone receptorâ€'positive (HR+)/human epidermal growth factor receptor 2â€'negative (HER2â€") advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. Breast, 2018, 41, S11-S12.	0.9	0
363	Reply to the letter to the editor â€˜Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analysesâ€™ by Kaiser et al.. Annals of Oncology, 2018, 29, 1878.	0.6	0
364	Biosimilars for HER2-Positive Breast Cancer. , 2019, , 231-237.		0
365	A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2â€" ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR. Breast, 2019, 48, S48.	0.9	0
366	Corrigendum to â€œEfficacyÂ+ safety of palbociclib (P) in patients (pts) â‰¥50 y with hormone receptorâ€'positive (HR+)/human epidermal growth factor receptor 2â€'negative (HER2â€") advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studiesâ€•[Breast 41S1 (2018) S11â€"12]. Breast, 2020, 49, 131.	0.9	0
367	Identifying tests related to breast cancer care in claims data. Breast Journal, 2020, 26, 1227-1230.	0.4	0
368	Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment. Breast Journal, 2020, 26, 1472-1474.	0.4	0
369	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clinical Cancer Research, 2020, 26, 4743-4747.	3.2	0
370	Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer. , 2021, , .		0
371	Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. Clinical Cancer Research, 2021, 27, 3275-3277.	3.2	0
372	In Reply. Oncologist, 2021, 26, e1286-e1287.	1.9	0
373	Expert Discussion: Predictive Markers. Breast Care, 2021, 16, 1-6.	0.8	0
374	THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2â€") ADVANCED BREAST CANCER (ABC). Breast, 2021, 59, S49.	0.9	0
375	Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorshipâ€"Associated Distress: Survey Study. JMIR Cancer, 2022, 8, e31756.	0.9	0
376	Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. Clinical Advances in Hematology and Oncology, 2018, 16, 533-537.	0.3	0
377	Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. Clinical Advances in Hematology and Oncology, 2019, 17, 486-489.	0.3	0
378	Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. Journal of Oncology, 2022, 2022, 1-9.	0.6	0

#	Article	IF	Citations
379	Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study.. Journal of Clinical Oncology, 2022, 40, 1101-1101.	0.8	0
380	Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.. Journal of Clinical Oncology, 2022, 40, 510-510.	0.8	0
381	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, 535-535.	0.8	0
382	Imaging of solid tumors using 68Ga-FAP-2286.. Journal of Clinical Oncology, 2022, 40, 3059-3059.	0.8	0